UK E-INFRASTRUCTURE, BARRIERS AND BENEFITS: AN INDUSTRY
PERSPECTIVE Darren Green FRSC GlaxoSmithKline Slide 2 Life sciences
and the UK economy The UK life science industry is one of the world
leaders; it is the third largest contributor to economic growth in
the UK with more than 4,000 companies, employing around 160,000
people and with a total annual turnover of over 50 billion. Its
success is key to future economic growth and to our goal to
rebalance the economy towards making new products and selling them
to the world. Globally the industry is changing with more focus on
collaboration, out-sourcing of research and earlier clinical trials
with patients David Cameron, 5 th December 2011 Slide 3 The R&D
Productivity Gap Source: Burrill & Company; US Food and Drug
Administration. Note: NMEs do not include BLAs Slide 4 Slide 5
>40 internal engines 35 external engines Corporate Venture Fund
GSK network c. 2010 Slide 6 Science Diverse applications Molecule
Design Disease & pathway modelling Biomarker discovery Trial
Design Patient Stratification Pharmacovigilance etc Requires a
Diverse e-infrastructure Slide 7 E-infrastructure ecosystem Janet
Slide 8 Potential Benefits Application of e-science to life
sciences challenges faster R&D to better products
Agrochemicals, drugs, diagnostics, treatment regimes Facilitation
of collaborations, knowledge transfer, innovation Slide 9 Industry
use of UK e-infrastructure In the domain of high performance
computing for life sciences, the Science and Technology Facilities
council (STFC) runs an e-science project with a 10- year history.
We are not aware of any life science company that makes of these
resources* * Response from the industry leads of the EU OpenPhacts
IMI project to UK Research Council 2012 Slide 10 E-infrastructure
barriers Janet CTAGCATG. Slide 11 Summary UK e-infrastructure
underutilised by Life Sciences industry Investments in hardware
need balancing by investments in people, skills & software
Realise the potential of the UK in E-health Train the next
generation of scientists the data scientist Facilitate
collaborations between industry and academia Proof of concept
studies Data sharing Slide 12 Acknowledgements Douglas KellBBSRC
Ian DixAstraZeneca Robert GlenUniversity of Cambridge Peter
CoveneyUniversity College London Anne-Marie CoriatMRC Lesley
ThompsonEPSRC ELC Life sciences members Contributors to the ELC
Life Sciences report Sophia AnaniadouUniversity of Manchester Andy
BrassUniversity of Manchester Klaus BengstAstra Zeneca David
BurtRoslin Institute Andy EllisBiocats Jonathan EssexUniversity of
Southampton Wendy FilsellUnilever Paul FinnInhibox Chris
FoleyGlaxoSmithKline Mark ForsterSyngenta Keith GodfreyUniversity
of Southampton Lee HarlandIndependent Consultant Vincent
HughesFujitsu UK Janette JonesUnilever Amanda LaneUnilever Chris
LarminieGlaxoSmithKline Louise LeongABPI Nick LynchAstra Zeneca Ian
MitchellFujitsu UK Chris MolloyIDBS Paul MortensenAstex
Pharmaceuticals Christine OrengoUniversity College London Chris
Page GlaxoSmithKline Anthony RoweJohnson & Johnson Philippe
SanseauGlaxoSmithKline Willie Taylor NIMR Janet ThorntonEMBL-EBI
Jon WrennallFujitsu UK
